The Immunohistochemical Analysis of RCAS1, HLA-G, and B7H4-Positive Macrophages in Partial and Complete Hydatidiform Mole in Both Applied Therapeutic Surgery and Surgery Followed by Chemotherapy

American Journal of Reproductive Immunology

Volumn 65, Issue 2, 2011, Pages 164-172

  Basta, Paweł ^a,b   Galazka, Krystyna ^a   Mach, Pawel ^a,b   Jozwicki, Wojciech ^b   Walentowicz, Malgorzata ^b   Wicherek, Lukasz ^a,b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

B7H4; HLA G; RCAS1

Indexed keywords

CELL PROTEIN; HLA G ANTIGEN; PROTEIN B7H4; PROTEIN RCAS1; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CHEMOTHERAPY; CLINICAL ARTICLE; CURETTAGE; DISEASE COURSE; ENDOMETRIUM; FEMALE; HOST RESISTANCE; HUMAN; HUMAN TISSUE; HYDATIDIFORM MOLE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; MACROPHAGE; PRIORITY JOURNAL; TROPHOBLAST;

ANTIGENS, CD80; ANTIGENS, NEOPLASM; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; HYDATIDIFORM MOLE; IMMUNOHISTOCHEMISTRY; MACROPHAGES; PREGNANCY; UTERINE NEOPLASMS;

EID: 78650990136     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/j.1600-0897.2010.00897.x     Document Type: Article

References (60)

1. Wilczyński JR: Cancer and pregnancy share similar mechanisms of immunological escape. Chemotherapy 2006; 52:107-110.
2. Wilczyński JR, Kalinka J, Radwan M: The role of the T-regulatory cells in pregnancy and cancer. Front Biosci 2008; 13:2275-2289.
3. + CTL activity within the human female reproductive tract: influence of stage of the menstrual cycle and menopause. J Immunol 1997; 158:3017-3027.
4. Beier HM, Beier-Hellwig K: Molecular and cellular aspects of endometrial receptivity. Hum Reprod Update 1998; 4:448-458.
5. Starkey PM, Clover LM, Rees MC: Variation during the menstrual cycle of immune cell populations in human endometrium. Eur J Obstet Gynecol Reprod Biol 1991; 39:203-207.
6. King A, Burrows T, Loke YW: Human uterine natural killer cells. Nat Immun 1996; 15:41-52.
7. Gardner L, Moffett A: Dendritic cells in the human decidua. Biol Reprod 2003; 69:1438-1446.
8. Salamonsen LA, Zhang J, Brasted M: Leukocyte networks and human endometrial remodelling. J Reprod Immunol 2002; 57:95-108.
9. Salamonsen LA, Lathbury LJ: Endometrial leukocytes and menstruation. Hum Reprod Update 2000; 6:16-27.
10. Hunt JS, Miller L, Platt JS: Hormonal regulation of uterine macrophages. Dev Immunol 1998; 6:105-110.
11. Renaud SJ, Graham CH: The role of macrophages in utero-placental interactions during normal and pathological pregnancy. Immunol Invest 2008; 37:535-564.
12. Knöfler M: Critical growth factors and signalling pathways controlling human trophoblast invasion. Int J Dev Biol 2010; 54:269-280.
13. Gustafsson C, Mjösberg J, Matussek A, Geffers R, Matthiesen L, Berg G, Sharma S, Buer J, Ernerudh J: Gene expression profiling of human decidual macrophages: evidence for immunosuppressive phenotype. PLoS ONE 2008; 3: e2078.
14. Dutsch-Wicherek M, Tomaszewska R, Lazar A, Wicherek L, Skladzien J: The association between RCAS1 expression in laryngeal and pharyngeal cancer and its healthy stroma with cancer relapse. BMC Cancer 2009; 9:35.
15. Wicherek L, Basta P, Pitynski K, Marianowski P, Kijowski J, Wiatr J, Majka M: The characterization of the subpopulation of suppressive B7H4(+) macrophages and the subpopulation of CD25(+) CD4(+) and FOXP3(+) regulatory T-cells in decidua during the secretory cycle phase, Arias Stella reaction, and spontaneous abortion - a preliminary report. Am J Reprod Immunol 2009; 61:303-312.
16. Wicherek L, Popiela TJ, Galazka K, Dutsch-Wicherek M, Opławski M, Basta A, Klimek M: Metallothionein and RCAS1 expression in comparison to immunological cell activity in endometriosis, endometrial adenocarcinoma, and the endometrium according to menstrual cycle changes. Gynecol Oncol 2005; 99:622-630.
17. Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P, Chen L, Coukos G, Zou W: Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007; 67:8900-8905.
18. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, Lackner A, Alvarez X, Ochoa A, Chen L, Zou W: B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006; 203:871-881.
19. Nakashima M, Sonoda K, Watanabe T: Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med 1999; 5:938-942.
20. Sonoda K, Miyamoto S, Hirakawa T, Yagi H, Yotsumoto F, Nakashima M, Watanabe T, Nakano H: Association between RCAS1 expression and microenvironmental immune cell death in uterine cervical cancer. Gynecol Oncol 2005; 97:772-779.
21. Sonoda K, Miyamoto S, Hirakawa T, Yagi H, Yotsumoto F, Nakashima M, Watanabe T, Nakano H: Invasive potency related to RCAS1 expression in uterine cervical cancer. Gynecol Oncol 2005; 99:189-198.
22. Sonoda K, Miyamoto S, Nakashima M, Wake N: The biological role of the unique molecule RCAS1: a bioactive marker that induces connective tissue remodeling and lymphocyte apoptosis. Front Biosci 2008; 13:1106-1116.
23. Sonoda K, Miyamoto S, Hirakawa T, Kaku T, Nakashima M, Watanabe T, Akazawa K, Fujita T, Nakano H: Association between RCAS1 expression and clinical outcome in uterine endometrial cancer. Br J Cancer 2003; 89:546-551.
24. Sonoda K, Kaku T, Hirakawa T, Kobayashi H, Amada S, Sakai K, Nakashima M, Watanabe T, Nakano H: The clinical significance of tumor-associated antigen RCAS1 expression in the normal, hyperplastic, and malignant uterine endometrium. Gynecol Oncol 2000; 79:424-429.
25. Choi IH, Zhu G, Sica GL, Strome SE, Cheville JC, Lau JS, Zhu Y, Flies DB, Tamada K, Chen L: Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol 2003; 171:4650-4654.
26. Miyatake T, Tringler B, Liu W, Liu SH, Papkoff J, Enomoto T, Torkko KC, Dehn DL, Swisher A, Shroyer KR: B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecol Oncol 2007; 106:119-127.
27. Pistoia V, Morandi F, Wang X, Ferrone S: Soluble HLA-G: Are they clinically relevant? Semin Cancer Biol 2007; 17:469-479.
28. Contini P, Ghio M, Poggi A, Filaci G, Indiveri F, Ferrone S, Puppo F: Soluble HLA-A, -B, -C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol 2003; 33:125-134.
29. Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R: A class I antigen, HLA-G, expressed in human trophoblasts. Science 1990; 248:220-223.
30. Eidukaite A, Tamosiunas V: Soluble HLA-G in the peritoneal fluid of women with endometriosis. Fertil Steril 2008; 89:465-467.
31. Kawashima M, Maeda N, Adachi Y, Takeuchi T, Yamamoto Y, Izumiya C, Hayashi K, Furihata M, Udaka K, Fukaya T: Human leukocyte antigen-G, a ligand for the natural killer receptor KIR2DL4, is expressed by eutopic endometrium only in the menstrual phase. Fertil Steril 2009; 91:343-349.
32. Wang F, Wen Z, Li H, Yang Z, Zhao X, Yao X: Human leukocyte antigen-G is expressed by the eutopic and ectopic endometrium of adenomyosis. Fertil Steril 2008; 90:1599-1604.
33. Basta P, Mach P, Pitynski K, Bednarek W, Klimek M, Zietek J, Zajac K, Wicherek L: Differences in the blood serum levels of soluble HLA-G concentrations between the menstrual cycle phases and menopause in patients with ovarian endometriosis and uterine leiomyoma. Neuro Endocrinol Lett 2009; 30:91-98.
34. Davidson B, Elstrand MB, McMaster MT, Berner A, Kurman RJ, Risberg B, Trope CG, Shih IeM: HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol Oncol 2005; 96:42-47.
35. Dutsch-Wicherek M, Wicherek L: The association of RCAS1 Serum concentration with the reversibility or irreversibility of the process of immune cytotoxic activity restriction during the normal menstrual cycle, cancer relapse, and surgical treatment for various types of squamous cell carcinomas and adenocarcinomas. Am J Reprod Immunol 2008; 59:266-275.
36. Rebmann V, Regel J, Stolke D, Grosse-Wilde H: Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol 2003; 13:371-377.
37. Rebmann V, Wagner S, Grosse-Wilde H: HLA-G expression in malignant melanoma. Semin Cancer Biol 2007; 17:422-429.
38. Urosevic M, Kurrer MO, Kamarashev J, Mueller B, Weder W, Burg G, Stahel RA, Dummer R, Trojan A: Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 2001; 159:817-824.
39. Nagymanyoki Z, Callahan MJ, Parast MM, Fulop V, Mok SC, Berkowitz RS: Immune cell profiling in normal pregnancy, partial and complete molar pregnancy. Gynecol Oncol 2007; 107:292-297.
40. Arruvito L, Sanz M, Banham AH, Fainboim L: Expansion of CD4+CD25+and FOXP3+ regulatory T cells during the follicular phase of the menstrual cycle: implications for human reproduction. J Immunol 2007; 178:2572-2578.
41. Aluvihare VR, Kallikourdis M, Betz AG: Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 2004; 5:266-271.
42. + regulatory T cells in decidua with respect to the progression of labor at term and the lack of analogical changes in the subpopulation of suppressive B7-H4 macrophages--a preliminary report. Am J Reprod Immunol 2009; 61:136-146.
43. Somerset DA, Zheng Y, Kilby MD, Sansom DM, Drayson MT: Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset. Immunology 2004; 112:38-43.
44. Fulop V, Mok SC, Gati I, Berkowitz RS: Recent advances in molecular biology of gestational trophoblastic diseases. A review. J Reprod Med 2002; 47:369-379.
45. Goldman-Wohl D, Ariel I, Greenfield C, Hochner-Celnikier D, Lavy Y, Yagel S: A study of human leukocyte antigen G expression in hydatidiform moles. Am J Obstet Gynecol 2001; 185:476-480.
46. Dutsch-Wicherek M, Tomaszewska R, Lazar A, Strek P, Wicherek L, Piekutowski K, Jozwicki W: The evaluation of metallothionein expression in nasal polyps with respect to immune cell presence and activity. BMC Immunol 2010; 11:10.
47. Enjoji M, Kotoh K, Nakashima M, Yoshimoto T, Miyagi Y, Kohjima M, Nakamuta M: RCAS1-expressing macrophages in inflammatory liver diseases. Liver Int 2006; 26:385-387.
48. Knoeller S, Lim E, Aleta L, Hertwig K, Dudenhausen JW, Arck PC: Distribution of immunocompetent cells in decidua of controlled and uncontrolled (choriocarcinoma/hydatidiform mole) trophoblast invasion. Am J Reprod Immunol 2003; 50:41-47.
49. Hussein MR, Abd-Elwahed AR, Abodeif ES, Abdulwahed SR: Decidual immune cell infiltrate in hydatidiform mole. Cancer Invest 2009; 27:60-66.
50. Pongcharoen S, Searle RF, Bulmer JN: Placental Fas and Fas ligand expression in normal early, term and molar pregnancy. Placenta 2004; 25:321-330.
51. Shih IeM: Gestational trophoblastic neoplasia--pathogenesis and potential therapeutic targets. Lancet Oncol 2007; 8:642-650.
52. Lewis CE, Pollard JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66:605-612.
53. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD: Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010; 362:875-885.
54. Tsagozis P, Eriksson F, Pisa P: Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages. Cancer Immunol Immunother 2008; 57:1451-1459.
55. Daisuke N, Komohara Y, Murazama T: Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL). Pathol Int 2010; 60:278-283.
56. Takayama H, Nishimura K, Tsujimura A, Nakai Y, Nakayama M, Aozasa K, Okuyama A, Nonomura N: Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation. J Urol 2009; 181:1894-1900.
57. Emens LA: Chemotherapy and tumor immunity: an unexpected collaboration. Front Biosci 2008; 13:249-257.
58. Chen R, Alvero AB, Silasi DA, Mor G: Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. Am J Reprod Immunol 2007; 57:93-107.
59. Garnett CT, Schlom J, Hodge JW: Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res 2008; 14:3536-3544.
60. Vicari AP, Luu R, Zhang N, Patel S, Makinen SR, Hanson DC, Weeratna RD, Krieg AM: Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother 2009; 58:615-628.